
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cerebrovasc Dis Extra</journal-id><journal-id journal-id-type="iso-abbrev">Cerebrovasc Dis Extra</journal-id><journal-id journal-id-type="publisher-id">CEE</journal-id><journal-title-group><journal-title>Cerebrovascular Diseases Extra</journal-title></journal-title-group><issn pub-type="epub">1664-5456</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27603933</article-id><article-id pub-id-type="pmc">5040888</article-id><article-id pub-id-type="doi">10.1159/000448897</article-id><article-id pub-id-type="publisher-id">cee-0006-0071</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Early Blood Pressure Lowering Does Not Reduce Growth of Intraventricular Hemorrhage following Acute Intracerebral Hemorrhage: Results of the INTERACT Studies</article-title></title-group><contrib-group><contrib contrib-type="author"><collab>The INTERACT Investigators</collab></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Craig S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arima</surname><given-names>Hisatomi</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Saxena</surname><given-names>Anubhav</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moullaali</surname><given-names>Tom J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Delcourt</surname><given-names>Candice</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Guojun</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jinchao</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Guofang</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lavados</surname><given-names>Pablo M.</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stapf</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Thompson</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chalmers</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>The George Institute for Global Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, N.S.W., Australia</aff><aff id="aff2"><sup>b</sup>Central Clinical School, University of Sydney, Sydney, N.S.W., Australia</aff><aff id="aff3"><sup>c</sup>Department of Neurology, Hebei Yutian Hospital, Tangshan, China</aff><aff id="aff4"><sup>d</sup>Department of Neurology, Xuzhou Central Hospital, Xuzhou, China</aff><aff id="aff5"><sup>e</sup>Servicio de Neurolog&#x000ed;a, Departamento de Medicina, Cl&#x000ed;nica Alemana, Universidad del Desarrollo, Santiago, Chile</aff><aff id="aff6"><sup>f</sup>Departmento de Ciencias Neurol&#x000f3;gicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile</aff><aff id="aff7"><sup>g</sup>CRCHUM, Universit&#x000e9; de Montr&#x000e9;al et Neurologie Vasculaire, H&#x000f4;pital Notre-Dame - CHUM, Montr&#x000e9;al, Que., Canada</aff><aff id="aff8"><sup>h</sup>Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease, University of Leicester, Leicester, UK</aff><author-notes><corresp id="cor1">*Prof. Craig S. Anderson, The George Institute for Global Health, PO Box M201, Missenden Road, Sydney, NSW 2050 (Australia), E-Mail <email>canderson@george.org.au</email></corresp><fn fn-type="other"><p>Clinical trial registration: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link> (unique identifier: NCT00716079).</p></fn></author-notes><pub-date pub-type="collection"><season>Sep-Dec</season><year>2016</year></pub-date><pub-date pub-type="epub"><day>8</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>9</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>6</volume><issue>3</issue><fpage>71</fpage><lpage>75</lpage><history><date date-type="received"><day>15</day><month>4</month><year>2016</year></date><date date-type="rev-recd"><day>12</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 by S. Karger AG, Basel</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.</license-p></license></permissions><abstract><sec><title>Background</title><p>Intraventricular hemorrhage (IVH) extension is common following acute intracerebral hemorrhage (ICH) and is associated with poor prognosis.</p></sec><sec><title>Aim</title><p>To determine whether intensive blood pressure (BP)-lowering therapy reduces IVH growth.</p></sec><sec><title>Methods</title><p>Pooled analyses of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT1 and INTERACT2) computed tomography (CT) substudies; multicenter, open, controlled, randomized trials of patients with acute spontaneous ICH and elevated systolic BP, randomly assigned to intensive (&#x0003c;140 mm Hg) or guideline-based (&#x0003c;180 mm Hg) BP management. Participants had blinded central analyses of baseline and 24-hour CT. Association of BP lowering to IVH growth was assessed in analysis of covariance.</p></sec><sec><title>Results</title><p>There was no significant difference in adjusted mean IVH growth following intensive (n = 228) compared to guideline-recommended (n = 228) BP treatment (1.6 versus 2.2 ml, respectively; p = 0.56). Adjusted mean IVH growth was nonsignificantly greater in patients with a mean achieved systolic BP &#x02265;160 mm Hg over 24 h (3.94 ml; p trend = 0.26).</p></sec><sec><title>Conclusions</title><p>Early intensive BP-lowering treatment had no clear effect on IVH in acute ICH.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Stroke</kwd><kwd>Intracerebral hemorrhage</kwd><kwd>Intraventricular hemorrhage</kwd><kwd>Hypertension</kwd><kwd>Intensive blood pressure lowering</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><ref-count count="7"/><page-count count="5"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1_1"><title>Introduction</title><p>Approximately one third of patients with acute spontaneous intracerebral hemorrhage (ICH) have intraventricular hemorrhage (IVH) extension, which confers a worse prognosis [<xref rid="B1" ref-type="bibr">1</xref>]. High blood pressure (BP) is associated with both hematoma growth and poor outcome [<xref rid="B2" ref-type="bibr">2</xref>], but limited data exist on the relationship of BP and IVH [<xref rid="B3" ref-type="bibr">3</xref>]. We aimed to determine whether BP-lowering therapy is associated with IVH growth among participants of the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT1 and INTERACT2) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>].</p></sec><sec sec-type="methods" id="sec1_2"><title>Methods</title><p>The INTERACT studies were international, multicenter, prospective, open, blinded-endpoint, randomized controlled trials, described in detail elsewhere [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. They involved 3,243 ICH patients (&#x0003c;6 h of onset; 404 INTERACT1, 2,839 INTERACT2) and elevated systolic BP (150-220 mm Hg) randomly assigned to intensive (target systolic BP &#x0003c;140 mm Hg) or guideline-recommended (&#x0003c;180 mm Hg) BP management. In predefined computed tomography (CT) substudies, 1,310 consecutive patients (346 INTERACT1, 964 INTERACT2) had a second CT at 24 &#x000b1; 3 h. ICH and IVH volume analyses were performed centrally by expert assessors blind to other data using MIStar version 3.2 (Apollo Medical Imaging Technology). The ethics committees approved the study protocols and written informed consent was obtained from the patients or appropriate surrogates.</p><p>Absolute increase in IVH volume was log-transformed to remove skewness and to achieve near-normal distribution of data for analyses. The association of randomized BP-lowering treatment on the absolute increase in IVH volume over 24 h was assessed in analysis of covariance (ANCOVA), adjusted for age, sex, baseline IVH volume, ICH location and volume, and China region. The mean achieved systolic BP over 24 h was calculated from the average of 1, 6, 12, 18, and 24 h postrandomization readings; their association with absolute increase in IVH volume was assessed by ANCOVA adjusting for the same variables, and also for use of statin therapy, baseline systolic BP, and randomized treatment. A p value &#x0003c;0.05 was considered statistically significant and SAS version 9.3 (SAS Institute, Cary, N.C., USA) was used in all analyses.</p></sec><sec sec-type="results" id="sec1_3"><title>Results</title><p>There were 456 CT substudy participants with IVH and available data (online suppl. fig. <xref ref-type="supplementary-material" rid="S1">1</xref>; for all online suppl. material, see <ext-link ext-link-type="uri" xlink:href="http://www.karger.com/doi/10.1159/000448897">www.karger.com/doi/10.1159/000448897</ext-link>). Guideline-treated patients were more likely to be female, but otherwise there were no significant differences in baseline characteristics, including time from onset to randomization, BP, as well as ICH and IVH volumes (table <xref ref-type="table" rid="T1">1</xref>).</p><p>No significant differences were observed in absolute or adjusted mean IVH growth between intensive and guideline BP-lowering treatment [3.4 (95% confidence interval 1.2-5.5) vs. 4.8 ml (2.7-6.9), p = 0.35; 1.6 (0.2-3.1) vs. 2.2 (0.8-3.7), p = 0.56, respectively]. Patients with an achieved systolic BP over 24 h &#x02265;160 mm Hg were younger, more likely to be from China, and had a higher baseline BP (online suppl. table <xref ref-type="supplementary-material" rid="S1">1</xref>). There was a nonsignificant trend towards a greater absolute and adjusted mean IVH growth of 3.58 ml (1.56-5.72) and 3.94 ml (1.46-6.61), respectively, with a mean achieved systolic BP over 24 h &#x02265;160 mm Hg (fig. <xref ref-type="fig" rid="F1">1</xref>). Patients with IVH growth were older, had higher National Institutes of Health Stroke Scale (NIHSS) scores, larger 24-hour ICH volumes, and smaller baseline IVH volumes (online suppl. table <xref ref-type="supplementary-material" rid="S1">2</xref>). The odds ratio for death or major disability was significantly greater with than without IVH growth (adjusted odds ratio 3.51, 95% confidence interval 2.05-6.02; online suppl. table <xref ref-type="supplementary-material" rid="S1">3</xref>).</p></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>This post hoc analysis of 456 IVH patients from the INTERACT CT substudies showed no clear relationship between IVH growth in acute ICH and a strategy of early intensive BP management, supporting an earlier analysis of the INTERACT2 study of no association of BP and IVH volume [<xref rid="B1" ref-type="bibr">1</xref>]. Thus, the clinical benefits of intensive BP lowering on functional outcome seen in the INTERACT studies are likely attributable to mechanisms other than IVH expansion.</p><p>These results concur with a previous small prospective cohort study, where again no significant difference in admission systolic BP or mean BP across categories of IVH volumes within the first 24 h of ICH onset was reported [<xref rid="B5" ref-type="bibr">5</xref>]. However, the mean 24-hour IVH volume was still higher in our standard BP treatment group, though not significantly different from intensive BP lowering. BP should not be excluded as a contributing factor to IVH growth. Whilst baseline BP per se does not appear to be a major factor in the pathogenesis of IVH, there was a trend towards a greater IVH volume growth at higher average achieved systolic BP over the first 24 h. Indeed, further analyses of the INTERACT2 study showed that rapid and sustained systolic BP reduction was associated with less ICH hematoma growth over 24 h [<xref rid="B6" ref-type="bibr">6</xref>]. Another consideration relates to whether intensive BP reduction is associated with a lower risk of developing IVH. We previously reported that delayed IVH is associated with a worse prognosis, though neither intensive BP lowering nor deep location of ICH were significantly associated with delayed IVH [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>Whilst the strengths to this study include having a robust, well-characterized cohort from large international trials with standardized care, there are several limitations that include the exclusion of patients with large ICH volumes and impaired Glasgow Coma Scale, which makes the results less generalizable to more severe ICH. Furthermore, despite the large sample size, it is still too small to provide precise estimates of a modest effect of early intensive BP lowering on IVH.</p><p>In summary, early intensive BP lowering according to the INTERACT protocol had no clear effect on IVH growth, although the lowest IVH growth was achieved in patients with sustained BP control over 24 h.</p></sec><sec id="sec1_5"><title>Disclosure Statement</title><p>T. Robinson reports consultancy payments from Bayer, Boehringer Ingelheim and Daiichi Sankyo, and his institution has received grant funding from the National Institute of Health Research, the British Heart Foundation, the Stroke Association, and the Engineering and Physical Sciences Research Council. J. Chalmers reports grants from the NHMRC during the conduct of the study, grants from Servier International outside the submitted work, and being a chief or co-chief investigator for other large stroke trials. C.S. Anderson reports grant support from the NHMRC, advisory board fees from Astra Zeneca and Medtronic, and speaker fees from Takeda China. The remaining authors have nothing to disclose.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><p>Supplementary data</p></caption><media xlink:href="cee-0006-0071-s01.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgment</title><p>The INTERACT studies were supported by research grants from the National Health and Medical Research Council (NHMRC) of Australia, which played no role in study design, conduct, analyses, or reporting.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Moullaali</surname><given-names>TJ</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Delcourt</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Lavados</surname><given-names>PM</given-names></name><name><surname>Stapf</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>T</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><collab>INTERACT2 Investigators</collab></person-group><article-title>Significance of intraventricular hemorrhage in acute intracerebral hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial results</article-title><source>Stroke</source><year>2015</year><volume>46</volume><fpage>653</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">25677598</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Stapf</surname><given-names>C</given-names></name><name><surname>Delcourt</surname><given-names>C</given-names></name><name><surname>Lindley</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>T</given-names></name><name><surname>Lavados</surname><given-names>P</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Hata</surname><given-names>J</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Parsons</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Heritier</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Simes</surname><given-names>RJ</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><collab>INTERACT2 Investigators</collab></person-group><article-title>Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>2355</fpage><lpage>2365</lpage><pub-id pub-id-type="pmid">23713578</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohwaki</surname><given-names>K</given-names></name><name><surname>Yano</surname><given-names>E</given-names></name><name><surname>Nagashima</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Nakagomi</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name></person-group><article-title>Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement</article-title><source>Stroke</source><year>2004</year><volume>35</volume><fpage>1364</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">15118169</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Skulina</surname><given-names>C</given-names></name><name><surname>Parsons</surname><given-names>MW</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Tao</surname><given-names>QL</given-names></name><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Jiang</surname><given-names>JD</given-names></name><name><surname>Tai</surname><given-names>LW</given-names></name><name><surname>Zhang</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>E</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Heritier</surname><given-names>S</given-names></name><name><surname>Morgenstern</surname><given-names>LB</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><collab>INTERACT Investigators</collab></person-group><article-title>Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT): a randomised pilot trial</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">18396107</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortes Lima</surname><given-names>TT</given-names></name><name><surname>Prandini</surname><given-names>MN</given-names></name><name><surname>Gallo</surname><given-names>P</given-names></name><name><surname>Cavalheiro</surname><given-names>S</given-names></name></person-group><article-title>Prognostic value of intraventricular bleeding in spontaneous intraparenchymal cerebral hemorrhage of small volume: a prospective cohort study</article-title><source>Neurosurgery</source><year>2012</year><volume>70</volume><fpage>929</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">21993187</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carcel</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Stapf</surname><given-names>C</given-names></name><name><surname>Sandset</surname><given-names>EC</given-names></name><name><surname>Delcourt</surname><given-names>C</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>T</given-names></name><name><surname>Lavados</surname><given-names>P</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><collab>INTERACT2 Investigators</collab></person-group><article-title>Degree and timing of intensive blood pressure lowering on hematoma growth in intracerebral hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial-2 results</article-title><source>Stroke</source><year>2016</year><volume>47</volume><fpage>1651</fpage><lpage>1653</lpage><pub-id pub-id-type="pmid">27143274</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moullaali</surname><given-names>TJ</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rabinstein</surname><given-names>AA</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Carcel</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Robinson</surname><given-names>T</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Delcourt</surname><given-names>C</given-names></name><name><surname>Stapf</surname><given-names>C</given-names></name><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Lindley</surname><given-names>RI</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><collab>INTERACT Investigators</collab></person-group><article-title>Prognostic significance of delayed intraventricular haemorrhage in the INTERACT studies</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2016</year><comment>Epub ahead of print</comment></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Intraventricular volume growth by average achieved BP between 1 and 24 h after randomization. <sup>&#x02020;</sup> Assessed by ANCOVA adjusting for age, sex, China region, use of statin, baseline systolic BP, randomized treatment, baseline IVH volume, and ICH location. Because of skewed raw data, adjusted means are reported with 95% confidence intervals obtained by back-transformation.</p></caption><graphic xlink:href="cee-0006-0071-g01"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of patients by randomized treatment</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">Intensive group (n = 228)</th><th align="left" rowspan="1" colspan="1">Guideline group (n = 228)</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Demographics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Age, years</td><td align="left" rowspan="1" colspan="1">67 (13)</td><td align="left" rowspan="1" colspan="1">68 (12)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">75 (33%)</td><td align="left" rowspan="1" colspan="1">97 (43%)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chinese region</td><td align="left" rowspan="1" colspan="1">113 (50%)</td><td align="left" rowspan="1" colspan="1">112 (49%)</td><td align="left" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" colspan="3" rowspan="1">Medical history</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Previous IVH</td><td align="left" rowspan="1" colspan="1">15 (7%)</td><td align="left" rowspan="1" colspan="1">17 (8%)</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Previous ischemic stroke</td><td align="left" rowspan="1" colspan="1">23 (10%)</td><td align="left" rowspan="1" colspan="1">28 (12%)</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heart disease</td><td align="left" rowspan="1" colspan="1">10 (4%)</td><td align="left" rowspan="1" colspan="1">9 (4%)</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="left" rowspan="1" colspan="1">161 (71%)</td><td align="left" rowspan="1" colspan="1">168 (74%)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">32 (14%)</td><td align="left" rowspan="1" colspan="1">27 (12%)</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" colspan="3" rowspan="1">Medication history</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antihypertensive agent</td><td align="left" rowspan="1" colspan="1">119 (52%)</td><td align="left" rowspan="1" colspan="1">118 (52%)</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Oral anticoagulant</td><td align="left" rowspan="1" colspan="1">18 (8%)</td><td align="left" rowspan="1" colspan="1">14 (6%)</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antiplatelet therapy</td><td align="left" rowspan="1" colspan="1">38 (17%)</td><td align="left" rowspan="1" colspan="1">40 (18%)</td><td align="left" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lipid-lowering therapy</td><td align="left" rowspan="1" colspan="1">27 (12%)</td><td align="left" rowspan="1" colspan="1">26 (11%)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" colspan="3" rowspan="1">Clinical features</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Time from onset to randomization</td><td align="left" rowspan="1" colspan="1">3.7 (2.7&#x02013;4.7)</td><td align="left" rowspan="1" colspan="1">3.5 (2.8&#x02013;4.7)</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Systolic BP</td><td align="left" rowspan="1" colspan="1">181 (17)</td><td align="left" rowspan="1" colspan="1">181 (17)</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diastolic BP</td><td align="left" rowspan="1" colspan="1">99 (15)</td><td align="left" rowspan="1" colspan="1">100 (15)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Glasgow Coma Scale score<xref ref-type="table-fn" rid="T1F1"><sup>1</sup></xref></td><td align="left" rowspan="1" colspan="1">14 (12&#x02013;15)</td><td align="left" rowspan="1" colspan="1">14 (12&#x02013;15)</td><td align="left" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NIHSS score<xref ref-type="table-fn" rid="T1F2"><sup>2</sup></xref></td><td align="left" rowspan="1" colspan="1">14 (9&#x02013;18)</td><td align="left" rowspan="1" colspan="1">14 (9&#x02013;19)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NIHSS score &#x02265;15</td><td align="left" rowspan="1" colspan="1">102 (45%)</td><td align="left" rowspan="1" colspan="1">113 (50%)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" colspan="3" rowspan="1">CT findings</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Time from onset to first CT, h</td><td align="left" rowspan="1" colspan="1">1.8 (1.3&#x02013;2.6)</td><td align="left" rowspan="1" colspan="1">1.8 (1.2&#x02013;2.5)</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline hematoma volume, ml</td><td align="left" rowspan="1" colspan="1">13.3 (7.5&#x02013;27.5)</td><td align="left" rowspan="1" colspan="1">12.3 (7.3&#x02013;25.7)</td><td align="left" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;24-hour hematoma volume, ml</td><td align="left" rowspan="1" colspan="1">13.9 (7.8&#x02013;34.0)</td><td align="left" rowspan="1" colspan="1">13.7 (8.0&#x02013;40.2)</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline IVH volume</td><td align="left" rowspan="1" colspan="1">2.5 (0.2&#x02013;9.6)</td><td align="left" rowspan="1" colspan="1">3.2 (0.0&#x02013;12.6)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;24-hour IVH volume</td><td align="left" rowspan="1" colspan="1">4.3 (1.5&#x02013;12.5)</td><td align="left" rowspan="1" colspan="1">6.4 (1.6&#x02013;15.3)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline deep location of hematoma</td><td align="left" rowspan="1" colspan="1">186 (82%)</td><td align="left" rowspan="1" colspan="1">199 (87%)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline intraventricular hematoma extension</td><td align="left" rowspan="1" colspan="1">178 (78%)</td><td align="left" rowspan="1" colspan="1">171 (75%)</td><td align="left" rowspan="1" colspan="1">0.44</td></tr></tbody></table><table-wrap-foot><fn><p>Data are n (%), mean &#x000b1; SD, or median (IQR).</p></fn><fn id="T1F1"><label>1</label><p>Scores on the Glasgow Coma Scale range from 15 (fully conscious) to 3 (deep coma).</p></fn><fn id="T1F2"><label>2</label><p>Scores on the NIHSS range from 0 (normal neurologic status) to 42 (coma with quadriplegia).</p></fn></table-wrap-foot></table-wrap></floats-group></article>